Signos Tirzepatide Review: Cost, a Bundled CGM & Honest Verdict (2026)

Signos (Signos+): a metabolic-health platform bundling clinician-prescribed compounded semaglutide with an FDA-cleared continuous glucose monitor (CGM) and app — pairing the medication with real-time glucose insights, a genuine differentiator from medication-only competitors. Every fact here comes from the company's own published program.

Tirzepatide availability isn't confirmed

Worth flagging directly: Signos's program clearly shows compounded semaglutide, but tirzepatide availability is not confirmed — only semaglutide is shown in the published program. Confirm directly whether tirzepatide is actually offered before assuming this review applies to that specific molecule.

What Signos is

Signos is a metabolic-health platform, that bundles compounded GLP-1 medication with an FDA-cleared CGM and app, with real-time glucose insights and coaching to help sustain results after treatment. Free rapid shipping and HSA/FSA eligibility are included.

What Signos costs

The program starts at $199/month on a 6-month program — the headline price is a program rate, not a month-to-month figure — with the CGM included at no extra cost.

The brand-vs-compounded question

Signos dispenses compounded semaglutide, not the FDA-approved branded product; compounded tirzepatide's actual availability wasn't confirmed. Compounded GLP-1s are pharmacy-made, not themselves FDA-approved finished drugs, and were not the specific products studied in the pivotal trials. See our guide to whether compounded tirzepatide is still legal in 2026 for the regulatory picture.

How the care model holds up

Signos's real strengths is a genuine FDA-cleared CGM bundled at no extra cost, real-time glucose insights and app coaching to sustain results, free rapid shipping, and HSA/FSA eligibility. The trade-offs: tirzepatide availability isn't confirmed — only semaglutide is shown, the headline $199 price is a 6-month program rate, not month-to-month, and the compounding pharmacy partner and state availability aren't published on the landing page. As with any GLP-1 program, and especially if you specifically want tirzepatide, confirm directly whether it's offered; tirzepatide carries labeled warnings for acute pancreatitis, gallbladder disease, and a boxed thyroid C-cell tumor warning — see our guides on Zepbound side effects, the gallbladder risk, and the thyroid cancer warning.

Does the drug work? (Separate from the provider)

Judge the provider on price, oversight and disclosure; judge the molecule on its trials. Tirzepatide's are strong — roughly 15–21% of body weight over 72 weeks in SURMOUNT-1¹, and better than semaglutide head-to-head² — but they were run on the brand drug at FDA-approved doses. Our tirzepatide evidence guide has the full picture.

The honest verdict

Signos's genuinely bundled FDA-cleared CGM is a real differentiator for glucose-guided weight loss, but confirm directly whether tirzepatide is actually offered, since only semaglutide is shown in the published program. For a confirmed tirzepatide provider with dietitian support, compare it against Shapely or CoreAge Rx. See our best tirzepatide providers ranking for the full field.